Search Within

Alexander Meyer Lesokhin

Formats
  1. Meeting Abstract (251)
  2. Journal Article (99)
  3. Research Letter (11)
  4. Review (7)
  5. Correspondence (3)
  6. Book Section (2)
  7. Editorial (2)
Groups
  1. Center for Hematologic Malignancies (375)
  2. Department of Medicine (375)
  3. Hematologic Malignancies Research (375)
  4. Hematologic Malignancies, Division of (375)
  5. Myeloma (375)
  6. Survivorship Research (221)

More Groups

People
  1. Hani Hassoun (199)
  2. Heather Landau (184)
  3. Sergio Giralt (182)
  4. David Chung (174)
  5. Neha Korde (170)
  6. Sham Mailankody (167)

More People

Years
  1. 2025 (6)
  2. 2024 (52)
  3. 2023 (77)
  4. 2022 (51)
  5. 2021 (31)
  6. 2020 (18)

More Years

Publications
  1. Blood (140)
  2. Clinical Lymphoma, Myeloma and Leukemia (57)
  3. Journal of Clinical Oncology (40)
  4. Biology of Blood and Marrow Transplantation (13)
  5. Leukemia and Lymphoma (13)
  6. Blood Advances (11)

More Publications

Publishers
  1. American Society of Hematology (151)
  2. Elsevier Inc. (78)
  3. American Society of Clinical Oncology (40)
  4. Nature Publishing Group (24)
  5. American Association for Cancer Research (14)
  6. Taylor & Francis Group (13)

More Publishers

Results (375)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Interim analysis of the 2nd chance protocol: A multicenter trial of daratumumab, carfilzomib, lenalidomide, & dexamethasone for relapsed/refractory myeloma with salvage autologous hematopoietic cell transplantation
    Meeting Abstract

    Shah, G. L.; Bal, S.; Rodriguez, C.; Chhabra, S.; Bayer, R. L.; Costa, L. J.; Lambird, J.; Ferrer, C.; Parascondola, A.; Marcello, L.; more...
    Transplantation and Cellular Therapy (2022)

    Fulltext@MSK | Save
  • Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience
    Research Letter

    Mohan, M.; Becnel, M. R.; Shah, U. A.; Dong, H.; Gundarlapalli, S.; Peterson, T.; Orozco, J. S.; Horowitz, S.; Chhabra, S.; Dhakal, B.; more...
    American Journal of Hematology (2022)

    Fulltext@MSK | Save
  • Capture rate of V(D)J sequencing for minimal residual disease detection in multiple myeloma
    Journal Article

    Hultcrantz, M.; Rustad, E. H.; Yellapantula, V.; Jacob, A.; Akhlaghi, T.; Korde, N.; Mailankody, S.; Lesokhin, A. M.; Hassoun, H.; Smith, E. L.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Nutrition perceptions, needs and practices among patients with plasma cell disorders
    Research Letter

    Malik, M. A.; Sweeney, N. W.; Jafri, M.; Derkach, A.; Chmielewski, C.; Adintori, P. A.; Mailankody, S.; Korde, N.; Tan, C. R.; Hassoun, H.; more...
    Blood Cancer Journal (2022)

    Fulltext@MSK | Save
  • Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis
    Journal Article

    Piedra, K.; Peterson, T.; Tan, C.; Orozco, J.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Lesokhin, A.; Shah, U.; Lu, S.; more...
    British Journal of Haematology (2022)

    Fulltext@MSK | Save
  • Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls
    Research Letter

    Shah, U. A.; Rögnvaldsson, S.; Derkach, A.; Björkholm, M.; Turesson, I.; David, Y.; Hultcrantz, M.; Tan, C.; Hassoun, H.; Korde, N.; more...
    Haematologica (2022)

    Fulltext@MSK | Save
  • Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed/refractory multiple myeloma (RRMM): Updated results from an ongoing phase I study
    Meeting Abstract

    Trudel, S.; Cohen, A. D.; Krishnan, A. Y.; Fonseca, R.; Spencer, A.; Berdeja, J. G.; Lesokhin, A.; Forsberg, P. A.; Laubach, J. P.; Costa, L. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Daratumumab versus lenalidomide maintenance therapy for multiple myeloma: A randomized pilot study comparing patient-reported health related quality of life measures
    Meeting Abstract

    Shah, U. A.; Malik, M.; Werner, K.; Burge, M.; Devlin, S. M.; Mailankody, S.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Tan, C.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A pilot plant-based dietary intervention in overweight and obese patients with monoclonal gammopathy of undetermined significance and smoldering multiple myeloma- the Nutrition Prevention (NUTRIVENTION) study
    Meeting Abstract

    Shah, U. A.; Alicea, D.; Adintori, P. A.; Burge, M.; Blaslov, J.; Derkach, A.; Mailankody, S.; Korde, N.; Tan, C.; Hultcrantz, M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients with relapsed or refractory multiple myeloma: Results from MagnetisMM-1
    Meeting Abstract

    Sebag, M.; Raje, N. S.; Bahlis, N. J.; Costello, C.; Dholaria, B.; Solh, M.; Levy, M. Y.; Tomasson, M. H.; Dube, H.; Damore, M. A.; more...
    Blood (2021)

    Fulltext@MSK | Save